CSCIED

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Clinical Research. 2025; 9: (1) ; 179-181 ; DOI: 10.12208/j.ijcr.20250051.

Clinical efficacy of atorvastatin combined with Tongxinluo in the treatment of community coronary heart disease patients
阿托伐他汀联合通心络治疗社区冠心病患者的临床效果

作者: 丁楠 *

北京市延庆区旧县镇社区卫生服务中心 北京

*通讯作者: 丁楠,单位:北京市延庆区旧县镇社区卫生服务中心 北京;

发布时间: 2025-01-18 总浏览量: 105

摘要

目的 本文重点对阿托伐他汀与通心络联合治疗对策展开研究,探讨其对社区冠心病患者身体健康状况的影响。方法 取我社区2023年1月到2024年1月100例冠心病患者作为研究对象,并将接受阿托伐他汀单药治疗者(50例)分在参照组,将接受阿托伐他汀与通心络联合治疗者(50例)分在研究组,观察治疗效果,分别统计患者治疗有效率、炎性因子指标、血脂水平、不良反应各项数据,并以此来判定治疗方案的可行性。结果 治疗有效率见研究组较高、参照组偏低;CRP、TNF-α、IL-6炎性因子指标见研究组偏低、参照组偏高;TC、TG、LDL-C、HDL-C血脂指标见,TC、TG、LDL-C各项研究组低于参照组,HDL-C见研究组高于参照组;不良反应见研究组较低、参照组较高;两组数据对比有明显差异(P<0.05)。结论 阿托伐他汀与通心络联合治疗的应用可有效提高社区冠心病患者治疗有效率,能够有效降低血脂水平、抑制炎性反应,且患者的安全性良好,同时可改善患者的生活质量,应用效果理想,价值较高,可推广。

关键词: 阿托伐他汀;通心络;联合治疗;社区冠心病

Abstract

Objective This paper focuses on the combination of atorvastatin and heart heart therapy, and discusses its effects on the health status of community CHD patients.
Methods I community 100 from January 2023 to January 2024 patients with coronary heart disease, and will receive atorvastatin monotherapy (50 cases) in the reference group, will receive atorvastatin and combination therapy (50 cases) in the study group, observe the treatment effect, respectively statistics patients treatment efficiency, inflammatory factor index, blood lipid level, adverse reactions data, and to determine the feasibility of treatment plan.
Results Treatment response was high in the study group and low in the reference group; CRP, TNF- α, IL-6 showed low study group and high reference group; TC, TG, LDL-C, HDL-C and HDL-C lipid index, TC, TG, LDL-C were lower than the reference group; HDL-C was higher in the study group than the reference group; adverse reactions were low in the study group and the reference group were higher; the data between the two groups was significantly different (P <0.05).
Conclusion   The application of atorvastatin and heart heart combination therapy can effectively improve the treatment efficiency of community patients with coronary heart disease, effectively reduce the blood lipid level, inhibit the inflammatory reaction, and the safety of patients is good, and can improve the quality of life of patients. The application effect is ideal, the value is high, and can be promoted.

Key words: Atorvastatin; Heart; Combination therapy; Community coronary heart disease

参考文献 References

[1] 王成恒. 阿托伐他汀联合通心络治疗社区冠心病患者的临床效果[J]. 河北医药,2022,44(12):1858-1861. 

[2] 肖翠红. 社区冠心病患者阿托伐他汀钙片联合通心络胶囊的临床效果[J]. 健|康必读,2023(10):93-94. 

[3] 陈泽江,黄修献,萧少武. 通心络胶囊联合阿托伐他汀治疗对老年冠心病患者血脂水平及心功能的影响[J]. 中国老年学杂志,2023,43(13):3086-3088. DOI:10.3969/j.issn.1005-9202.2023.13.004.

[4] 张杰群,张铁民. 通心络胶囊联合阿托伐他汀钙对冠心病并颈动脉粥样硬化斑块患者的疗效探讨[J]. 中外医疗,2023,42(13):98-101. 

[5] 高秋,徐亮,陈皖华. 通心络胶囊联合阿托伐他汀钙片治疗冠心病合并高脂血症的效果研究[J]. 中外医疗,2022, 41(35): 176-180. 

[6] 李挺. 通心络胶囊联合阿托伐他汀治疗冠心病不稳定型心绞痛效果观察[J]. 中国乡村医药,2021,28(6):40-41. 

[7] 周婷. 通心络胶囊联合阿托伐他汀钙片治疗冠心病合并高脂血症的临床效果[J]. 临床合理用药杂志,2021,14(29): 32-34. 

[8] 张转利,高莉. 阿托伐他汀联合通心络胶囊治疗冠心病伴发高脂血症的临床效果[J]. 临床医学研究与实践,2020, 5(24): 146-148. 

[9] 张岩. 通心络、氨氯地平联合阿托伐他汀钙治疗高血压并冠心病的效果及药学分析[J]. 黑龙江医药,2020,33(6): 1278-1280. 

[10] 李然. 通心络联合阿托伐他汀治疗冠心病不稳定型心绞痛的效果及对高敏C-反应蛋白的影响[J]. 世界最新医学信息文摘(连续型电子期刊),2020,20(3):175,177. 

引用本文

丁楠, 阿托伐他汀联合通心络治疗社区冠心病患者的临床效果[J]. 国际临床研究杂志, 2025; 9: (1) : 179-181.